93319-65-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyridazinylmethylamine, 97%, is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and medications.
Used in Agrochemical Industry:
3-Pyridazinylmethylamine, 97%, is used as an intermediate in the synthesis of agrochemicals, playing a crucial role in the development of pesticides, herbicides, and other agricultural chemicals to improve crop protection and yield.
Used in Research and Development:
3-Pyridazinylmethylamine, 97%, is used as a research chemical to explore its potential applications and properties in various chemical reactions and processes, contributing to the advancement of scientific knowledge and innovation in the field of chemistry.

InChI:InChI=1/C5H7N3/c6-4-5-2-1-3-7-8-5/h1-3H,4,6H2

Upstream product

• 53896-49-4 pyridazine-3-carbonitrile 
• 52348-44-4 pyridazine-3-carbaldehyde oxime 
• 1632-76-4 3-methylpyridazine 

Downstream Products

• 530090-26-7 (Z)-2-{1-[2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(pyridazin-3-ylmethyl)acetamide 
• 1439358-04-9 C₁₈H₁₆N₄O₃S 
• 1613149-05-5 7-[2-(5-methyl-1-phenyl-1H-benzimidazol-2-yl)ethyl]imidazo[1,5-b]pyridazine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists

A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives was synthesized, and their structure-activity relationships were examined in order to identify potent and selective arginine vasopressin V2 receptor agonists. Attempts to substitute other chemical groups in place of the 2-pyridilmethyl moiety of 1a led to the discovery that potent V2 binding affinity could be obtained with a wide range of functional groups. This structural tolerance allowed for the manipulation of other attributes, such as selectivity against V1a receptor affinity or avoidance of the undesirable inhibition of cytochrome P450 (CYP), without losing potent affinity for the V2 receptor. Some representative compounds obtained in this study were also found to decrease urine volume in awake rats.

ORGANIC COMPOUNDS

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

CB1 MODULATOR COMPOUNDS

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

HISTAMINE ANTAGONIST TRIADIAZOLE DERIVATIVES, COMPOSITIONS, AND METHOD OF USE THEREFOR

New 3,4-diamino-1,2,5-thiadiazole oxide derivatives which are histamine H 1-antagonists. A specific compound of this invention is 3-3-N-(4-fluorobenzyl)-N-pyrid-2-yl-amino!propylamino!-4-pyrimidin-4-yl-methylamino!-1,2,5-thiadiazole-1-oxide.